Addendum

Apalutamide (prostate cancer) - Addendum to Commission A20-20

Report documents

Indication:

Patients with metastatic hormone-sensitive prostate cancer

Result of dossier assessment:

Conclusion of dossier assessment A20-20 unchanged; the inclusion of the CHAARTED study did not influence the result of the assessment.

Federal Joint Committee (G-BA)

2020-08-20: G-BA decision was published.

Project no.: A20-62
Commission: Commission awarded on 28.07.2020 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.